Current Report Filing (8-k)
March 19 2019 - 08:56AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report
(Date of earliest event reported): March 19, 2019
OncBioMune
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-52218
|
|
20-2590810
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
No.)
|
|
(IRS
Employer
Identification
No.)
|
11441
Industriplex Blvd, Suite 190.
Baton
Rouge, LA
|
|
70809
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(225)
227-2384
Registrant’s
telephone number, including area code
Not
applicable.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events
On
March 19, 2019, OncBioMune Pharmaceuticals, Inc. issued a press release announcing they have received notification
from Dana-Farber/Harvard Cancer Center that its Phase 2 clinical trial of ProscaVax, a PSA/IL-2/GM-CSF vaccine, in treatment-naïve
patients with clinically localized prostate cancer being conducted by Beth Israel Deaconess Medical Center (BIDMC) is officially
activated and recruiting patients. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
ONCBIOMUNE
PHARMACEUTICALS, INC.
|
|
|
|
Dated:
March 19, 2019
|
By:
|
/s/
Andrew A. Kucharchuk
|
|
Name:
|
Andrew A. Kucharchuk,
|
|
Title:
|
President and Chief Financial Officer
|